In a new job - February 5, 2022
Oncorena appoints Chief Scientific Officer
Oncorena has announced that Börje Haraldsson has joined the management team as Chief Scientific Officer. Professor Haraldsson, is one of the founders of Oncorena. Being a world leader in clinical and experimental renal research, he will bring a wealth of clinical experience and competence to the company, states the company. “It is truly a great […]
Clinical Trials - February 1, 2022
Oncorena initiates phase I-II clinical trial
Oncorena has announced the initiation of the Phase I-II clinical trial of orellanine in patients with advanced kidney cancer on dialysis. The drug candidate orellanine is being developed for organ-specific chemotherapy with curative potential for patients with advanced kidney cancer undergoing dialysis due to kidney failure. Preclinical evidence shows that orellanine specifically exerts powerful anti-tumor […]
Financing - January 3, 2022
Oncorena receives 66 million SEK
Oncorena receives a capital injection of 66 million SEK from one of the company’s principal shareholders together with two new investors. Under the terms of the agreement, Oncorena can receive an additional 94 million SEK in the future. The capital will primarily fund Oncorena’s first clinical study, a phase I/II study with orellanine in patients […]
Clinical Trials - March 2, 2021
The Swedish Medical Products Agency approves Oncorena’s Phase 1/2 trial
Oncorena has announced the Swedish Medical Products Agency’s approval of the Phase 1/2 of First in Patient trial of the compound orellanine in patients with metastatic renal cancer in dialysis. Preclinical evidence shows that orellanine, a well known fungus toxin, specifically exerts powerful anti-tumor effects on metastatic renal cancer in different preclinical models, states the […]
